Chronic anxiety is one of the longevity-psychiatry frame's most underappreciated cognitive risk factors. The biological substrate — sustained HPA axis activation, elevated cortisol burden, autonomic dysregulation, inflammatory load — produces measurable structural and functional brain changes that overlap substantially with the changes that drive cognitive decline and dementia risk. Patients with longstanding generalized anxiety, panic disorder, or chronic worry patterns are accumulating biological cost across the decades of illness; the cognitive trajectory of unmanaged chronic anxiety bends measurably in the wrong direction.
The hippocampal cost is the structural signature. Sustained glucocorticoid exposure produces dendritic atrophy in CA3 pyramidal neurons, suppression of adult neurogenesis in the dentate gyrus, and progressive volume reduction in the hippocampus. The Lupien and colleagues work showing accelerated cognitive decline in older adults with sustained cortisol elevation, the Sapolsky tradition of HPA-hippocampal interaction, and the imaging literature in chronic anxiety populations converge on the same picture: years of unmanaged anxiety produce measurable hippocampal volume reduction, and the volume reduction is correlated with the cognitive trajectory.
The executive function cost is the functional signature. Chronic anxiety produces ongoing demand on prefrontal cortex — inhibitory control over worry content, attention regulation in the face of distraction, working memory maintenance under threat states. The clinical correlate is the cognitive fog, attention difficulty, and decision-fatigue that anxious patients describe; the neuropsychological correlate is reduced performance on executive tasks; the long-term correlate is accelerated decline in executive domains. The patient with chronic anxiety is running their executive system above sustainable load for decades.
The autonomic substrate is the systemic signature. Reduced heart rate variability (Stage 11.2), elevated resting heart rate, blunted baroreflex sensitivity, and sustained sympathetic dominance characterize chronic anxiety. The autonomic dysregulation drives cardiovascular risk, inflammatory load, sleep disruption, and metabolic effects independently of the subjective anxiety experience. The patient with chronic anxiety is producing the cardiovascular and metabolic phenotype that drives much of the longevity cost of the illness; the autonomic substrate matters as much as the subjective experience.
The inflammatory contribution links anxiety to the broader brain-aging biology. Chronic anxiety is associated with elevated inflammatory markers (CRP, IL-6, TNF-alpha), and the inflammation contributes to depression risk, cardiovascular risk, and cognitive decline. The inflammation-anxiety relationship is bidirectional — anxiety drives inflammation through HPA and autonomic pathways; inflammation drives anxiety through brain mechanisms — and chronic patterns establish a self-reinforcing loop that produces accumulated biological cost. The longevity-psychiatry frame treats the inflammation as part of the anxiety, not as separate.
The clinical implication is to treat chronic anxiety as the cognitive risk factor it is. The patient with longstanding generalized anxiety who has been managed with inadequate treatment for years is accumulating measurable cost; the patient with anxiety who achieves durable remission is bending the trajectory toward a substantially better cognitive future. Effective evidence-based treatment — SSRIs and SNRIs for chronic anxiety, CBT for the behavioral foundation, autonomic interventions (HRV biofeedback, breath work) for the substrate, and selective adjuncts where appropriate — is one of the most powerful neuroprotective interventions available. Chronic anxiety is not just a quality-of-life problem. It is a longevity problem with measurable cognitive consequences, and the work of treating it well is some of the most important neuroprotection available in psychiatry.